Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.52 |
| ▸ | PPARD | Q03181 | 9/20 | 0.52 |
| ▸ | PPARG | P37231 | 9/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3906347 | 1.00 | PPARA (0.52) | PPARAPPARDPPARGKDM4EMEN1 | |
| SCHEMBL13791276 | 0.88 | PPARA (0.36) | PPARAPPARDPPARG | |
| SCHEMBL3905164 | 0.84 | PPARA (0.50) | PPARAPPARDPPARGKDM4EMEN1 | |
| SCHEMBL3906952 | 0.84 | PPARA (0.50) | PPARAPPARDPPARGKDM4EMEN1 | |
| SCHEMBL3905168 | 0.84 | PPARA (0.50) | PPARAPPARDPPARGKDM4EMEN1 | |
| SCHEMBL3906526 | 0.82 | PPARA (0.55) | PPARAPPARDPPARG | |
| SCHEMBL3904645 | 0.81 | PPARA (0.54) | PPARAPPARDPPARG | |
| SCHEMBL3912618 | 0.81 | PPARA (0.64) | PPARAPPARDPPARGKDM4EMEN1 | |
| SCHEMBL3906708 | 0.77 | PPARD (0.64) | PPARAPPARDPPARGKDM4EMEN1 | |
| SCHEMBL3904197 | 0.76 | PPARA (0.58) | PPARAPPARDPPARGKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1535915-A1 | FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TXN2, CYP11B2, CYP11B1 | PPARA 294/4885PPARD 214/4885PPARG 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.